Xuanzhu Biopharmaceutical Co., Ltd. announced that it has received an official notification from the China Securities Regulatory Commission (CSRC) confirming completion of its filing for an H-share full-circulation programme. The approval permits the one-to-one conversion of 357.25 million unlisted domestic shares—currently held by six shareholders—into H-shares tradable on the Hong Kong Stock Exchange’s Main Board.

Key details • Conversion scale: 357.25 million shares, equivalent to 68.97% of the company’s issued share capital. • Post-conversion structure: All 517.95 million issued shares will become H-shares, up from 31.03% previously, enabling full circulation in Hong Kong. • Major participating shareholders: – Xuanzhu (HK) Biopharmaceutical Limited: 215.29 million shares (41.57% post-conversion). – Sihuan Pharmaceutical Holdings Group Ltd.: 39.16 million shares (7.56%). – Metropolitan Industrial Investment Fund: 70.03 million shares (13.52%). – Future Industry Investment Fund II: 23.34 million shares (4.51%). – Shijiazhuang Keshuo Investment Centre: 8.17 million shares (1.58%). – Beijing SL Pharmaceutical Co., Ltd.: 1.25 million shares (0.24%).

Regulatory timeline • The CSRC approval is valid for 12 months from 26 March 2026. • Listing of the converted shares remains subject to Hong Kong Stock Exchange approval and other regulatory procedures.

Investors are advised to note that the conversion and listing have not yet been completed and remain conditional on the satisfaction of all regulatory requirements.